Hypertension. 1999;34:1025
(Hypertension. 1999;34:1025.)
© 1999 American Heart Association, Inc.
Nobel Laureates Honored by the Council for High Blood Pressure Research
Edward D. Frohlich, MD, Editor-in-Chief
L. Gabriel Navar, PhD
Richard N. Re, MD, Associate Editors
 |
Introduction
|
|---|
Top
Introduction
|
|---|
In this issue, we salute three more outstanding
scientists,
Robert F. Furchgott, PhD, Louis J. Ignarro, PhD, and Ferid
Murad,
PhD, who have been recognized in earlier years by the Council
for
High Blood Pressure Research and then, in 1998, were jointly
awarded
the Nobel Prize in Medicine for their important contributions.
In
1988, Dr Furchgott, who is the Distinguished Professor of
Pharmacology
at the State University of New York (SUNY) at Brooklyn,
and
Dr Murad, who is Chairman of the Department of Integrative Biology,
Pharmacology
and Physiology at the University of Texas Medical School
in
Houston, received the CIBA Award by the Council. And, in 1995,
the
Council honored Dr Ignarro, who is in the Department of
Pharmacology at
the University of California Los Angeles School
of Medicine in Los
Angeles, together with Dr Salvador Moncada
of the Wolfson Institute for
Biomedical Research, University
College in London.
The Nobel Prize in Medicine was awarded to Drs Robert F. Furchgott,
Louis J. Ignarro, and Ferid Murad in 1998 for their studies that led to
the important discovery of endothelial synthesis of
nitric oxide and its role in the local vasodilation of blood vessels
and of the signaling role of nitric oxide in the
cardiovascular and nervous systems. These scientists
important contributions to the overall understanding of the local
regulation of blood flow have already made tremendous impact on our
understanding of the pathophysiology of many
cardiovascular, renal, and neurological diseases.
Indeed, the concept of endothelial dysfunction with
aging, menopause, its association with the underlying
cardiovascular risk factors such as smoking and the
hyperlipidemias, and with the common co-morbid diseases
(eg, hypertension, atherosclerosis, diabetes mellitus,
and obesity) has become well known to the practicing physician in only
the past few years. The essential importance of
endothelial dysfunction has been the recent realization
that this abnormality is treatable, if not preventable, under certain
circumstances, using very common cardiovascular
pharmacological treatments which are already available.
Hypertension is delighted to highlight their award for this 20th
anniversary celebration of our journal.